Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carcinoma in situ.

D L Lamm1

  • 1Department of Urology, West Virginia University Health Sciences Center, Morgantown.

The Urologic Clinics of North America
|August 1, 1992
PubMed
Summary

Carcinoma in situ (CIS) treatment has shifted towards intravesical bacillus Calmette-Guerin (BCG) immunotherapy. Initial BCG offers high response rates and durable disease-free survival, with radical cystectomy reserved for refractory cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.

Urologic oncology·2011
Same author

Liposomal delivery of alpha-Interferon to murine bladder tumor cells via transferrin receptor-mediated endocytosis.

Drug delivery·2009
Same author

Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?

Cancer surveys·2004
Same author

Diet and nutrition in urologic cancer.

The West Virginia medical journal·2003
Same author

Immunotherapy for bladder cancer.

Current urology reports·2002
Same author

Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer.

Cancer detection and prevention·2001

Area of Science:

  • Urology
  • Oncology
  • Immunotherapy

Background:

  • Carcinoma in situ (CIS) is an aggressive bladder cancer with a variable prognosis.
  • Historically, radical cystectomy was the primary treatment for CIS.
  • Evolving treatment strategies now favor a more conservative approach due to treatment advancements.

Purpose of the Study:

  • To evaluate the shift in treatment paradigms for bladder carcinoma in situ.
  • To assess the efficacy of intravesical bacillus Calmette-Guerin (BCG) immunotherapy.
  • To compare BCG immunotherapy with radical cystectomy for CIS management.

Main Methods:

  • Review of treatment changes for bladder CIS.
  • Analysis of outcomes associated with intravesical BCG immunotherapy regimens.
  • Comparison of survival and quality of life data between BCG and cystectomy.

Main Results:

  • Intravesical BCG immunotherapy demonstrates a high complete response rate of 82%.
  • Over 75% of patients achieving a complete response remain disease-free for 5+ years.
  • Data do not currently support cystectomy as superior to initial BCG with salvage options.

Conclusions:

  • Intravesical BCG immunotherapy is a highly effective primary treatment for bladder CIS.
  • A conservative management approach with initial BCG is recommended.
  • Alternative therapies exist for patients who do not respond to BCG immunotherapy.

Related Experiment Videos